DwomoaAdu GhanaUniversity of Ghana Medical School

DwomoaAdu
Dwomoa Adu MD. FRCPnAfter a career as Consultant Nephrologist at the Queen Elizabeth Hospital and Senior Clinical Lecturer at the University of Birmingham, England I returned to Ghana in 2009 to take up an appointment as Honorary Consultant Nephrologist at the Korle Bu Teaching Hospital and Senior Research Fellow at the University of Ghana Medical School. I have a long standing research interest in the immunogenetics and treatment of lupus nephritis and ANCA associated vasculitis. My current research interests have been the prevalence, causes and genetics of chronic kidney disease in Africa. I am Co-PI together with Professor A. Ojo of the H3Africa Kidney Disease Research Network grant funded by the NIH to study the genomics of CKD in Africa. I am a past President of the African Association of Nephrology.
Institution

Day 1 - Sunday April 14, 2024

Time Session
9 a.m.
10:30 a.m.
APOL1 Targeted Therapies: Who to Test and Which Disease to Treat?
SK100
Fatiu AbiolaArogundade Chairperson NigeriaObafemi Awolowo University Teaching Hospitals Complex/ National Postgraduate Medical College of Nigeria
FernandaSales Luiz Vianna Chairperson fslvianna@gmail.comBrazilUniversidade Federal do Rio Grande do Sul
OpeyemiOlabisi Chairperson opeyemi.olabisi@duke.eduUnited StatesDuke University School of Medicine
  • Ethical Aspects of Race-based Genetic Testing
    AnaIltis Speaker iltisas@wfu.eduUnited StatesWake Forest University
  • Contribution of ApoL1 Risk Genotype to HIVAN
    SaraladeviNaicker Speaker South AfricaUniversity of the Witwatersrand
  • Contribution of APOL1 Risk Alleles to Kidney Disease in West Africa
    DwomoaAdu Speaker dwoms@blueyonder.co.ukGhanaUniversity of Ghana Medical School
  • Targeting ApoL1: A 12-Year Journey from Genetic Discovery to Phase 2 Trials
    OgoEgbuna Speaker ogo_egbuna@vrtx.comUnited StatesVertex Pharmaceuticals Inc
  • Q and A
Hall C2
11 a.m.
12 p.m.
Plenary Session 2: CrisprCas9 Therapy for Sickle Cell Diseases: How Do We Go from Discovery to Equitable Availability of Gene Therapy for All? (Obiageli Eunice Nnodu, Nigeria)
PL2
AgnesFogo Chairperson United States
GuillermoRosa Diez Chairperson guillermo.rosadiez@hospitalitaliano.org.arArgentinaHospital Italiano de Buenos Aires; Argentinean Society of Nephrology; Latinoamerican Society of Nephrology and Hypertension; International Society of Nephrology
  • My Story
    VictoriaGray Speaker vwright_03@yahoo.comUnited States
  • CrisprCas9 Therapy for Sickle Cell Diseases: How Do We Go from Discovery to Equitable Availability of Gene Therapy for All? Hugh de Wardener Lecture
    Obiageli EuniceNnodu Speaker oennodu@gmail.comNigeriaUniversity of Abuja
Hall A

Pre-Congress - Saturday April 13, 2024

Time Session
4:30 p.m.
6 p.m.
WCN'24 Opening Ceremony and Plenary Session 1: The Origin of the Universe (Daniel de Florian, Argentina)
OCPL1
  • ISN President's Address
    MasaomiNangaku Speaker Japan
  • Tribute to Stewart Cameron
  • Welcome by WHO Director of Non-Communicable Diseases Dr Bente Mikkelsen
  • Welcome by Dr. Marina Papaginovic, SAN President; Dr. Guillermo Rosa Diez, WCN Local Organising Group Chair; and Dr. Jorge Rico, SLANH President and WCN Local Organizing Group co-Chair
    GuillermoRosa Diez Speaker guillermo.rosadiez@hospitalitaliano.org.arArgentinaHospital Italiano de Buenos Aires; Argentinean Society of Nephrology; Latinoamerican Society of Nephrology and Hypertension; International Society of Nephrology
    JorgeRico Speaker jorgericof@yahoo.comColombia
    MariaPapaginovic Leiva Speaker drapapaginovicleiva@gmail.comArgentina
  • Welcome by Minister of Health for Buenos Aries Dr Fern
  • Welcome by SPWG Chair Alessia Fornoni
    AlessiaFornoni Speaker United StatesUniversity of Miami
  • The Origin of the Universe
    DanielDe Florian Speaker deflo@unsam.edu.arArgentinaUniversidad Nacional de San Martin
  • Acceptance Speech: Hamburger Award
    AdeeraLevin Speaker CanadaUniversity of British Columbia and Providence Health Care
Hall A